文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

CD38双特异性抗体XmAb18968治疗复发/难治性急性髓系白血病和T细胞急性淋巴细胞白血病

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2026-09-14

这项1期多中心临床试验评估了CD38-CD3双特异性T细胞衔接抗体XmAb18968在复发/难治性AML和T-ALL成人患者中的安全性和初步疗效。共入组22例患者(AML 13例,T-ALL 9例),中位年龄63岁。未观察到≥3级细胞因子释放综合征或神经毒性,部分患者获得缓解或疾病负荷改善,支持进一步研究CD38靶向治疗。

要点

  • XmAb18968在复发/难治性AML和T-ALL中安全性可耐受,无≥3级CRS或神经毒性。
  • 11例可评估RR-AML中1例达PR、2例达MRD阴性CR;6例RR-T-ALL中4例疾病负荷改善、1例MRD清除。
  • AML和T-ALL的中位OS分别为8.5个月和8.7个月。

核心结论

  • XmAb18968在复发/难治性AML和T-ALL中安全可耐受,并显示出令人鼓舞的初步疗效,支持进一步研究CD38靶向治疗。

研究设计与样本

  • 1期多中心临床试验,入组22例复发/难治性AML(n=13)和T-ALL(n=9)成人患者,中位年龄63岁(范围31-77)。
  • 既往治疗中位线数为3(范围1-8),包括维奈克拉(77.3%)、异基因造血干细胞移植(22.7%)、CD7 CAR-T细胞治疗和达雷妥尤单抗(11.1%)。

主要发现

  • ≥3级不良事件包括贫血(14%)、中性粒细胞减少(18%)和血小板减少(14%)。
  • 未观察到≥3级细胞因子释放综合征或神经毒性。
  • 17例患者(AML=11,ALL=6)完成至少一个周期治疗。
  • 11例RR-AML中,1例达部分缓解(PR),2例达MRD阴性完全缓解(CR)。
  • 6例RR-T-ALL中,4例疾病负荷获有意义改善,其中1例MRD清除。

临床怎么用

  • XmAb18968可作为复发/难治性AML和T-ALL的潜在CD38靶向治疗选择,尤其对多线治疗失败患者。
  • 治疗期间需监测贫血、中性粒细胞减少和血小板减少等血液学不良事件。

局限性

  • 样本量小(22例),为1期试验,疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD38 is a transmembrane glycoprotein highly expressed in acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). XmAb18968 is a novel CD38-CD3 bi-specific T-cell engager with Fc domain modified to reduce non-selective activation of effector cells. In this phase 1 multicenter clinical trial, we evaluated the outcomes of XmAb18968 in adults with relapsed/refractory (RR) AML and T-ALL. Twenty-two patients with AML (n = 13) and T-ALL (n = 9) with a median age of 63 years (range 31-77) were enrolled. Prior lines of therapy (median 3, range 1-8) included venetoclax (77.3%), allogeneic HCT (22.7%), CD7 CAR-T cell therapy and daratumumab (11.1%). Grade ≥3 adverse events included anemia (14%), neutropenia (18%), and thrombocytopenia (14%). No grade ≥3 cytokine release syndrome or neurotoxicity was seen. Overall, 17 patients (AML = 11, ALL = 6) completed at least one cycle of therapy. Among 11 patients with RR-AML, one achieved partial remission (PR) and two achieved MRD negative complete remission (CR). In 6 patients with RR-T-ALL, 4 achieved meaningful improvement in disease burden with 1 clearance of MRD. Median OS was 8.5 months in AML and 8.7 months in T-ALL. XmAb18968 is safe and tolerable with encouraging preliminary efficacy, supporting further investigation of CD38 targeting therapies in this setting (NCT05038644).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Guru Murthy GS, Shah B, Badar T, et al. Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42736326. doi:10.1038/s41375-026-03130-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。